Differential Regulation of the Circulating and Intrarenal RAS During Aging

Dr. Lewis K. Dahl identified many of the relationships that underlie our current thinking and focus of research on hypertension. Among the first to establish the interactions between salt and hypertension, the realization that genetic factors played a major role in how the kidney responded to salt loads led to development of the genetically predisposed Dahl salt-sensitive rat. His research, although not specifically directed toward aging, recognized that the effects of high-salt diets were not necessarily immediate. In fact, he suggested that at least one third of the life span was required for salt-induced changes in systolic blood pressure (SBP).

I am very grateful for the honor of presenting the Dahl lectureship on work, which, over the past several years, has had aging as the focus. The emphasis has been on the autonomic nervous system, as influenced by the renin-angiotensin system (RAS), specifically, the balance between angiotensin (Ang) II and Ang-(1-7) and the contributions of brain cardiovascular areas to the constellation of changes occurring with advancing age. The overall message derived is that, although the brain RAS plays a major role in all of the age-related changes in cardiovascular and metabolic function, neither the SBP nor the metabolic changes appear to be initiating factors in the activation of the intrarenal RAS or the decline in kidney function during aging (Figure 1).

Differential Regulation of the Circulating and Intrarenal RAS During Aging

Components of the classical circulating RAS, in particular, renin release from the juxtaglomerular cells of the kidney, undergo a decline in older animals. This includes reductions in renal tissue renin mRNA, juxtaglomerular cell renin content, responsiveness of renin release to various challenges, and plasma renin and angiotensin (Ang) II. The renal vasconstrictor responses to exogenously administered Ang II are increased in older animals, perhaps resulting from the reductions in the circulating system. In striking contrast, however, kidney Ang II content increases in older animals. This latter finding is not surprising, because all of the components of the RAS are synthesized locally within the kidney, and local production of Ang peptides is regulated independent of the circulating system. Thus, whereas the juxtaglomerular cell renin and its release into the circulation are considered representative of the circulating/hormonal RAS, renal tissue content, tubular fluid, or urinary RAS components are considered representative of the intrarenal RAS.

The concept of differential regulation of the circulating and intrarenal or other tissue RAS is not new. One possibility for these differences relates to the increase in SBP. An increase in arterial pressure during aging may lead to a baromediated reduction in renin release from the kidney, contributing to the decline in the circulating RAS. In contrast, for the intrarenal system, there is evidence that the regulation of tubular renin may be opposite to or at least different from that of the circulation. Although kidney Ang II content may reflect receptor-mediated uptake of the peptide, as well as local synthesis, urinary components representing the intrarenal RAS likely reflect a tubular site of synthesis and regulation. In Ang II–dependent hypertension, Ang peptides increase in the kidney but not in hypertension caused by high salt. For the intrarenal RAS, changes in glomerular filtration rate, either hyperfiltration or loss of nephrons, and reduced glomerular filtration rate may contribute to the independent regulation. In addition, the extent to which the metabolic dysfunction accompanying aging contributes to changes in the kidney is not completely known. The role of each of the above potential contributors to the regulation of the intrarenal RAS is emphasized in this review.
there was no young control group, it is not possible to determine whether lower intrarenal RAS in treated animals reflects the maintenance of normal young urinary peptide levels or lowering of RAS components below levels seen in young adult rats.

### Intrarenal RAS Regulation in Animals Without Age-Related Hypertension and Effects of Long-Term RAS Blockade

In the human population, as well as in a variety of rat strains, the numerous age-related pathologies commonly develop in association but are not entirely linked. In general, Wistar and Sprague-Dawley (SD) rats exhibit a more rapid aging process and shorter life span than other strains and tend to exhibit age-related impairments in cardiovascular, metabolic, and renal function, including elevations in SBP. The Fischer 344 rat represents an interesting model of aging, because insulin resistance and kidney damage occur without an increase in SBP.29,30 The Fischer 344 X Brown Norway rat expresses greater longevity than Fischer 344 animals with rescue from many of their age-related deficits, including the decline in renal function.31,32

In an attempt to rule out elevated SBP during aging as a contributor to activation of the intrarenal RAS, we studied male Fischer 344 rats between 3 and 15 months of age33 (Figure 3A). As expected, SBP did not increase and is actually lower in older than in younger rats. Contrary to what occurs in older rats and human subjects with an age-related increase in SBP, there is no decline in plasma Ang II. In terms of the intrarenal RAS, urinary Ang II is higher in older rats compared with young animals (Figure 3B) and is accompanied by marked increases in protein excretion. Serum leptin increases in older control rats relative to young rats with a similar trend for serum insulin (Figure 4). Serum glucose is higher in older than in younger rats, and older rats exhibit indices of reduced insulin sensitivity.33 Long-term (1-year) AT1 receptor blockade with L-158,809, a potent and selective antagonist, prevents increases in insulin, leptin, and glucose in older F344 rats, associated with reduced weight gain.33 There are no significant differences in SBPs between the older control and L-158,809-treated groups, and proteinuria, a marker of renal damage, is also completely prevented. Ang II excretion is maintained at levels similar to those of younger animals.33 Plasma Ang II is higher in treated than in untreated young or older rats, as evidence of effective AT1 receptor blockade for loss of AT1-mediated feedback control of renin.

### Figure 1. Diagram depicting the proposed relationships among SBP and metabolic dysfunction in the regulation of the intrarenal RAS and renal function during aging.

However, the decline in the circulating RAS9 raises questions about mechanisms underlying the beneficial effects of RAS blockade to reduce age-related impairments. We assessed effects of long-term RAS blockade on components of the intrarenal RAS in Wistar rats, a well-characterized model of aging with a life span of ≈24 months of age.20,21,24,25 When treated for 22 months starting at 2 months of age with either losartan or enalapril, these rats have lower SBPs than vehicle-treated older control rats.26 Treated rats also have a higher mitochondrial number, better learning and memory, less cardiac and renal fibrosis, and an extended life span.27 Accompanying the cardiovascular and renal improvements in the older animals, plasma Ang I and Ang II are elevated in the losartan-treated group and Ang I in the enalapril group (Figure 2), as expected from shorter-term studies with these treatments and consistent with interruption of the feedback inhibition of renin release.26 The urinary Ang peptides, in contrast, are lower in both treatment groups, illustrating markedly different regulation within these 2 compartments.26 The fact that plasma Ang peptides increase dramatically with long-term RAS blockade and urinary levels of the peptides decline renders filtration as the predominant source of urinary peptides unlikely. Although suppression of the intrarenal RAS may be responsible for the renoprotective effects,21 treated rats had lower pressure and improved overall renal function28; thus, it is not clear to what extent lower pressure contributes to improved renal function and secondarily to lower levels of urinary RAS peptides or vice versa.

### Figure 2. Urinary and plasma Ang peptides at 24 months of age in control Wistar rats (Con; n=7) or after 22-months treatment with enalapril (Enal; 10 mg/kg per day; n=7) or losartan (Los; 30 mg/kg per day; n=6). Ang peptides in the urine in all of the treatment groups were suppressed in comparison with plasma. *P<0.01 vs losartan; **P<0.01 and ***P<0.001 vs control. Data obtained from Reference 26.
release. Again, the differential regulation of systemic and intrarenal (urinary) Ang systems during long-term RAS blockade is clear.

The Fischer X Brown Norway rat is considered a model of “healthy aging,” because these animals have a ~36-month life span and less cardiovascular decline than SD or Wistar rats. A preliminary study illustrates that urinary Ang II and protein are maintained at low levels in a comparison of 9-month-old versus 30-month-old animals. Treatment of these rats for 6 months with an ACE inhibitor or AT1 receptor blocker beginning at 24 months of age decreased fat mass without lowering blood pressure. However, RAS blockade does not lower insulin or leptin relative to older control rats and does not alter the excretion of Ang II or protein. Thus, a different pattern of protein and Ang II excretion is evident in healthy aging as opposed to Fischer 344 rats, although neither rat exhibits elevated SBP as part of the aging process. From these studies, however, SBP appears to be independent of the intrarenal RAS activation (Figure 1).

Clinical trials show that RAS blockade, either by ACE inhibitors or AT1 receptor blockers, may substantially lower the risk for cardiac hypertrophy and new-onset type 2 diabetes in hypertensive subjects. However, the exact mechanism underlying this effect is unknown. Beneficial effects are reported most often in studies of hypertensive subjects, and certainly blocking activation of the intrarenal system might contribute to lowering of pressure systemically via less salt and water reabsorption at the tubular level or may prevent renal injury at the glomerulus by reductions in intraglomerular pressure. However, our study in Fischer 344 rats demonstrates the advantageous effects of RAS blockade on metabolic function and renal injury independent of SBP-lowering actions. With systemic treatments, improvements in metabolism and renal function may involve actions at the skeletal muscle, brain and autonomic nervous system, or other organs, such as the liver and pancreas. In addition, because RAS blockade prevents increases in leptin, glucose, and insulin, as well as activation of the intrarenal RAS, these studies do not illustrate which of the defects comes first, metabolic or renal, or which is directly or secondarily prevented by RAS blockade. Other studies presented below shed greater light on this point.

**Contribution of the Brain RAS to Regulation of the Intrarenal RAS During Aging**

The rationale for considering brain-kidney interactions in regulation of the intrarenal RAS was stimulated by a long-standing interest in the role of the renal nerves in control of renal function. An interesting report used an innovative molecular approach to address this interaction. A fusion protein leading to cellular generation of Ang II directly, without the need for processing enzymes, was placed behind a glial-fibrillary acid protein promoter for the generation of transgenic mice. The mice with targeted expression of Ang II generation and secretion to glial cells when backcrossed with angiotensinogen-deficient mice corrected the renal deficits characteristic of total angiotensinogen-deficient animals. This intriguing observation supports the concept that brain mechanisms involving the RAS could exert powerful effects on renal development and function.

Transgenic rats deficient in brain, or more precisely, glial angiotensinogen (ASrAogen), developed by Drs Ganten and Bader by insertion of angiotensinogen antisense driven by a glial-fibrillary acid protein leading to cellular generation of Ang II directly, without the need for processing enzymes, was placed behind a glial-fibrillary acid protein promoter in to the Hannover SD rat genome provide a unique tool to assess effects of the brain RAS on aging. The targeted disruption of glial angiotensinogen appears to preserve neuronal Ang peptides, and the renal deficits characteristic of total angiotensinogen-deficient animals. This intriguing observation supports the concept that brain mechanisms involving the RAS could exert powerful effects on renal development and function.

We compared ASrAogen rats with Hannover SD rats at what would be young adult (~15 weeks), middle age (~48 weeks), and early aging (~70 to 80 weeks of age for the Hannover SD strain). SBP is lower in young adult ASrAogen rats than in control Hannover SD, and they maintain low SBP (Figure 5). Older ASrAogen rats have some baroreflex impairment, but the gain or sensitivity of reflex control of the heart rate in older animals is comparable with that in younger SD rats, and heart rate remains low, as evidence of reduced cardiac sympathetic and/or enhanced parasympathetic nervous system activity. The life span is ~30% longer in ASrAogen
rats, and they maintain lower leptin, glucose, and insulin levels compared with age-matched SD rats or (mRen2)27 hypertensive rats. Body weight is lower at all of the time points in the face of increased food intake relative to age-matched SD rats, suggesting that absence of glial RAS leads to central nervous system–mediated improved energy metabolism. Thus, glial-derived Ang II appears to participate in the age-related impairments in autonomic function. Because older ASrAogen rats resemble animals on long-term systemic RAS blockade, we speculate that the beneficial effects of systemic treatment on the wide array of age-related deficits in function in Fischer 344, Wistar, or SD rats could involve blockade of the brain RAS. RAS blockers are thought to gain access to the brain with long-term treatment, but whether differences in the extent of brain RAS blockade track with effectiveness of therapy is under investigation. A recent study suggests that, in human subjects, cognitive decline is slowed to a greater extent, with RAS blockers having lipophilic properties.

The concept that targeted disruption of the glial RAS in ASrAogen rats influences activation of the intrarenal RAS during aging is being tested. Plasma Ang II declines in older SD rats coincident with higher SBP but not in age-matched ASrAogen rats that do not exhibit elevations in SBP. Urinary Ang II and protein are higher in SD rats at 48 weeks and 68 weeks as compared with 16 weeks of age, with little change in ASrAogen animals over this time frame. Insulin increases in SD rats at 68 weeks but not at the 48-week time point. This puts activation of the intrarenal RAS and development of proteinuria at time points preceding elevated SBP in ASrAogen animals over this time frame. Thus, the contribution of body weight, a factor known to play a role in renal injury, cannot be excluded from potential age-related causes of impairments in renal function.

In conclusion, the use of transgenic rats provides additional insight into the independent regulation of circulating and intrarenal RAS. Plasma Ang II and kidney renin mRNA decline significantly when SBP increases. The intrarenal RAS increases independently of hypertension and markers of insulin resistance. An increase in urinary Ang II occurs along with the proteinuria at the times tested, but precise determination of the time course of changes is lacking. Nonetheless, the ASrAogen rats are protected from age-related decline in cardiovascular, renal, and metabolic function and in this manner resemble animals treated long-term with RAS blockade.

**Time Course of Changes in Renal Function and Activation of the Intrarenal RAS**

The reduction in circulating levels of Ang II in SD rats during aging appears to occur coincident with increases in SBP rather than with the onset of kidney damage, as assessed by proteinuria or activation of the intrarenal RAS. Because Fischer 344 rats and ASrAogen rats do not have an increase in SBP, maintenance of normal circulating levels of RAS peptides may reflect the absence of pressure-mediated inhibition of renin release. On the other hand, intrarenal RAS elevation in SD and Fischer 344 rats occurs without increases in SBP. In SD rats, development of insulin resistance also occurs at a later time point than increases in proteinuria and the intrarenal RAS, suggesting that these age-related changes are not hypertension or hyperglycemia-related (Figure 1). In both Fischer 344 and SD rats, increases in Ang II and protein excretion over those of younger animals occur at 45 to 65 weeks of age, but whether activation of the intrarenal RAS is secondary to progressive renal damage or is an initiating factor is not known from the above studies. A more detailed assessment of the time course of activation of the intrarenal RAS relative to the elevation in proteinuria in aging SD rats is in progress. Ang II excretion assessed weekly from 24 to 40 weeks of age is stable or tends to decline in male SD rats, before the increase at >45 weeks of age. In contrast, protein excretion increases significantly at 34 weeks of age and continues to increase steadily thereafter, subsequent to a modest, transient increase in creatinine excretion between 24 and 27 weeks of age. Although we do not yet have serum creatinine data in these animals, the transient increase in urinary creatinine may be indicative of increased glomerular filtration, because it is not corrected by factoring for body weight. Interestingly, the increase in intrarenal Ang II excretion follows rather than precedes increases in urinary protein, which may place it secondary to a transient episode of hyperfiltration. Therefore, at present, increases in urinary protein would appear to be the best indicators of renal functional changes during the aging process, rather than markers of the intrarenal RAS, such as Ang II. Long-term RAS blockade prevents increases in both urinary protein and Ang peptide excretion in older animals; thus, the renoprotective effects may result at least in part from preventing the hyperfiltration and/or the increase in tubular protein as the
first step, which secondarily prevents activation of the intra-
renal RAS.

Hyperfiltration plays a role in early renal changes in dia-
etes,62 and hyperfiltration is prevented in streptozotocin-
induced diabetic rats in response to bilateral renal dererva-
tion.63 However, there are reports that renal nerves are
protective against the progression of diabetic nephropathy.64
Increases in the glomerular filtration rate in response to
amino acid load are also reduced by sectioning renal nerves.65
Because the glial angiotensinogen deficiency in ASrAogen
rats is associated with preservation of renal function and a
lack of change in protein or Ang II excretion during the aging
process, hyperfiltration initiated by changes in renal nerve
activity for control of glomerular hemodynamics is an attrac-
tive hypothesis. Indeed, in normotensive Wistar rats there is
an increase in renal norepinephrine content during middle age
that could be interpreted as consistent with increased renal
nerve activity.66 This potential mechanism may provide a link
between the age-related functional changes in the kidney and
the central nervous system.

Is Activation of the Intrarenal RAS
Characteristic of Other Tissue RAS
During Aging?

From the comparison of ASrAogen and SD rats, it is inferred
that the brain RAS (elevated or not) contributes to age-related
elevations in pressure, changes in metabolism, and activation
of the intrarenal RAS. There is a reduction in the endogenous
Ang-(1-7) tone within the solitary tract nucleus in brain
medulla oblongata for facilitation of reflex control of heart
rate and a reduction in neprilysin mRNA67 in older SD rats.
Premiminary studies show a trend for a reduction of neprilysin
activity in brain medullary tissue of older rats.68 A decline in
neprilysin activity in the plasma and kidney of older rats is
reported.9 Thus, a deficit in Ang-(1-7) by reduced formation
or enhanced production/reduced metabolism of Ang II may
underlie age-related changes and serve as the substrate for
impairments in autonomic control mechanisms.

There are reports of an increase in Ang II in cardiac tissue
in older rats,69 but data on regulation of the RAS in other
tissues during the aging process are minimal. It would be
interesting to know whether long-term treatments with RAS
blockers are associated with changes in the levels of Ang
peptides in tissues such as heart and brain, in addition to
suppressing the age-related increase in urinary Ang II.
Knowledge of whether the protective benefits of RAS inhib-
itors are related to tissue penetrability70 might help resolve
this issue. Finally, our preliminary studies in Fischer 344 X
Brown Norway rats reveal that these animals maintain low
levels of Ang II excretion to a late age, consistent with the
concept of health aging. Understanding the mechanisms
affording cardiovascular and renal protection in these animals
would aid the identification of common features of impair-
ment at earlier ages in Fischer 344, SD, and Wistar animals.

Overall Conclusions

Together, the accumulated data indicate that aging is associ-
ated with activation of the intrarenal RAS in several normo-
tensive strains of rats. The renal RAS activation is indepen-
dent of age-related increases in SBP. However, the decline in
circulating RAS during aging may be a consequence of the
age-related increase in pressure, because plasma Ang II does
not decline in rats without increased SBP during aging. Given
the differences in timing of the onset and development of
insulin resistance, renal injury as indicated by proteinuria,
and activation of the intrarenal RAS observed with increasing
age, all 3 of the age-related changes appear to be independent
of each other (Figure 1). The intrarenal RAS increase may
track with other markers of metabolic dysfunction, such as
elevated weight gain, but not insulin resistance. Whether
other indices of impaired autonomic function including
baroreflex dysfunction and elevated renal sympathetic nerve
activity contribute to changes in renal function or activation
of the renal RAS is yet to be demonstrated. There appears to
be an age-related decrease in Ang-(1–7) relative to Ang I or
Ang II in urine, plasma, and brain, which may be restored
with a long-term AT1 receptor or Ang-converting enzyme
blockade. Systemic RAS blockade or glial angiotensinogen
deficiency prevents other age-related changes, arguing
strongly for mechanisms involving the blockade of local
tissue RAS, brain and kidney in particular, as contributors to
protective effects of systemic RAS blockade during aging.

Acknowledgments

I express sincerest appreciation to my long-time colleagues for their
constant support, critical technical and intellectual input, and friend-
ship. Their contributions are reflected in numerous aspects of the
work presented in this review.

Sources of Funding

This work was supported by grants HL-51952 and HL-51952S1 from
the National Heart, Lung, and Blood Institute and National Cancer
Institute grant CA-122318. The American Heart Association-
MidAtlantic Affiliate pre-doctoral fellowship grant 0215151U (S.O.
Kasper), Unifi, Inc (Greensboro, NC), and the Farley-Hudson
Foundation (Jacksonville, NC) also provided partial support for this
work.

Disclosures

None.

References

1. Dahl LK. Possible role of salt intake in the development of essential
2. Baylis C. Renal responses to acute angiotensin II inhibition and admin-
istered angiotensin II in the aging, conscious, chronically catheterized rat.
4. Masliamani S, Zhang XZ, Baylis C. Blunted pressure natriuretic response
5. Reckelhoff JF, Baylis C. Proximal tubular metallothionein activity is
6. Thompson MM, Oyama TT, Kelly FJ, Kenefick TM, Anderson S. Activity
and responsiveness of the renin-angiotensin system in the aging
aging and with long-term converting enzyme inhibition in rats. Am J
Physiol. 1994;267:F35–F43.
9. Jung FF, Kenefick TM, Ingelfinger JR, Vora JP, Anderson S. Down-
regulation of the intrarenal renin-angiotensin system in the aging rat.


Lewis K. Dahl Memorial Lecture: The Renin-Angiotensin System and Aging
Debra I. Diz

Hypertension. 2008;52:37-43; originally published online May 12, 2008;
doi: 10.1161/HYPERTENSIONAHA.107.108985

Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2008 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/52/1/37

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org//subscriptions/